Targeting novel signaling pathways for resistant acute myeloid leukemia

Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5.

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.

Keywords: Acute myeloid leukemia; Novel therapies; Resistance; Signaling pathways.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adult
  • Child
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Drug Resistance, Neoplasm
  • Humans
  • Leukemia, Myeloid, Acute / metabolism*
  • Leukemia, Myeloid, Acute / therapy*
  • Molecular Targeted Therapy*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction*
  • TOR Serine-Threonine Kinases / metabolism
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • BCL2 protein, human
  • CREB1 protein, human
  • Cyclic AMP Response Element-Binding Protein
  • Proto-Oncogene Proteins c-bcl-2
  • STAT3 Transcription Factor
  • ARIH2 protein, human
  • Ubiquitin-Protein Ligases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases